A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to document the long term safety of a long-acting injectable
formulation of risperidone in the treatment of patients with schizophrenia who have
previously been treated with long-acting risperidone. Efficacy will also be evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.